Refacto Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The refacto market research report is one of a series of new reports that provides refacto market statistics, including refacto industry global market size, regional shares, competitors with a refacto market share, detailed refacto market segments, market trends and opportunities, and any further data you may need to thrive in the refacto industry. This refacto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to rising incidences of LSDs, rising cases of oral cancer, rising prevalence of hemophilia B, rising adoption of prophylactic treatments, and rising prevalence of chronic and complex diseases. Major trends in the forecast period include advancements in biotechnology and gene therapy, innovation in drug development, technological advancements in clotting factor products, advancements in gene therapy and gene editing, and technological advances in production and manufacturing.

The growing prevalence of hemophilia A is expected to drive the growth of the refacto market in the coming years. Hemophilia A is a genetic bleeding disorder caused by a deficiency or dysfunction of clotting factor VIII, leading to impaired blood clot formation and prolonged bleeding, even from minor injuries or spontaneously in severe cases. The increasing incidence of hemophilia A is attributed to better diagnosis, heightened awareness, improved access to healthcare, and advancements in genetic screening and treatment, which have contributed to more cases being identified and managed globally. Refacto (moroctocog alfa) is used to treat hemophilia A by replacing the deficient clotting factor VIII, preventing or controlling bleeding episodes and managing bleeding during surgeries. For example, a report from the World Federation of Hemophilia in October 2022 noted that in 2022, there were 427,685 individuals worldwide diagnosed with bleeding disorders, including 208,957 cases of hemophilia A. As a result, the increasing prevalence of hemophilia A is fueling the growth of the refacto market.

The rise in healthcare expenditure is also expected to accelerate the growth of the refacto market. Healthcare expenditure refers to the total amount spent on medical services, products, and public health initiatives aimed at maintaining and improving health. The increase in healthcare spending is driven by an aging population that requires more medical care, along with the rising prevalence of chronic diseases such as diabetes and heart conditions. Investments in healthcare expenditure related to Refacto support its development, production, and accessibility for treating hemophilia and similar conditions. This growing healthcare spending is beneficial for Refacto, as it drives demand for advanced treatments, improves access to therapy, promotes long-term cost savings through reduced hospitalizations, and enhances patient adherence to treatment, all of which contribute to market growth. For instance, a report published by the Office for National Statistics in May 2023 highlighted that between 2022 and 2023, healthcare spending in the UK increased by 5.6%, compared to just 0.9% growth in 2022, with total healthcare expenditure reaching approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is expected to fuel the growth of the refacto market.

The increasing number of drug approvals is also expected to support the growth of the refacto market. Drug approvals are the regulatory process in which agencies evaluate and authorize a drug for public use, ensuring it is safe, effective, and of high quality. The number of drug approvals is rising due to advancements in technology, streamlined regulatory processes, greater investment in biotechnology, and a focus on rare diseases and personalized medicine. Refacto, as a proven recombinant therapy for hemophilia A, has demonstrated consistent safety and efficacy in clinical trials, which supports regulatory confidence and accelerates the approval of similar innovative treatments for hemophilia. For example, according to the National Institutes of Health in January 2024, the U.S. Food and Drug Administration (FDA) approved 55 new drugs in 2023, compared to 37 in 2022. Therefore, the rising number of drug approvals is expected to drive the growth of the refacto market.

The key company operating in the refacto market is Pfizer Inc.

North America was the largest region in the refacto market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in refacto report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the refacto market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Refacto is a recombinant factor VIII therapy used to treat hemophilia A, a genetic disorder in which patients lack sufficient clotting factor, resulting in prolonged bleeding. It works by replacing the missing factor VIII, helping to prevent or manage bleeding episodes in affected individuals.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Refacto include prophylaxis, on-demand treatment, perioperative management, and immune tolerance induction (ITI). Prophylaxis refers to a preventive treatment strategy that aims to avoid the occurrence of a medical condition. In the case of hemophilia, prophylactic treatment involves regular infusions of clotting factor concentrates to prevent bleeding episodes before they occur. Refacto is available in formulations such as powder for injection and pre-filled syringes, and is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies. It is used by a wide range of patients, including pediatric, adult, and geriatric populations.

The refacto market consists of sales of products including recombinant factor VIII products, extended half-life recombinant factor VIII products, and plasma-derived factor VIII products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.